GILD Jan 2025 42.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:14PM EDT. Market open.
Loading interactive chart…
- Zacks
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
- GuruFocus.com
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)
© 2024 Yahoo. All rights reserved.